u/nils_tulloch

That is the 68-week readout, not the 72-week one. Different trial, different duration.

maintenance is where the logistics finally get boring, which is the point

Two years at maintenance. The logistics are the only remaining work — ordering, storing, remembering.

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

That is a range, not a trend. Two weigh-ins 22 days apart cannot distinguish them.

Questions about oral contraceptive absorption and gastric emptying are legitimate pharmacology questions with product-specific answers. A pharmacist can answer them properly; a board cannot.

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

maintenance is a phase, not a finish line

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

Small fix — you have described interval stretching and called it a dose reduction. The exposure profiles differ.

do not chase the last two kilos with a dose increase

Careful — the supplier does not control the last mile and most of your variance is in it.

Is that intention-to-treat or completers?

Telogen shedding follows a period of significant weight change rather than a specific compound, and it resolves.

open-label extensions are not the same evidence as the randomised phase

check who the comparator was before you compare anything

Correction: that was clearance time, not carrier time. The lane table separates them for exactly this reason.

Withdrawal studies in this class consistently show substantial regain after discontinuation. That is a pharmacological finding about a chronic condition, not a statement about anyone’s discipline.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

a press release is not a publication

trial populations get support that nobody on this board gets

registry entry, protocol, publication — three different documents

the goal weight you picked at week 1 was a guess

find the dose that holds, then stop optimising

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Cosigning on planning it in advance. Deciding what maintenance looks like while still losing is much easier than deciding it in a panic.

maintenance is a phase, not a finish line

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Same lane in a different season for comparison?

find the dose that holds, then stop optimising

A lane is an origin, a destination, a carrier and a season. Change any one and the distribution changes, which is why supplier-level shipping averages are close to meaningless.

Careful — the supplier does not control the last mile and most of your variance is in it.

honest_syringe19 is right about regional stock. It changes the shape of the distribution, not just the mean.

Clearance took three days and the carrier took nine. I had been blaming the wrong half for two years.

declared value and description are the shipper’s decision, ask what they use

the lowest effective dose is a real target and nobody talks about it

registry entry, protocol, publication — three different documents